Effects of amlodipine in patients with chronic heart failure

Area of Science:

• Cardiology
• Pharmacology

Background:

• The efficacy of calcium antagonists, like amlodipine, in managing ischemic heart failure remains uncertain.
• Patients with mild to moderate chronic heart failure often receive furosemide and angiotensin-converting enzyme inhibitors.

Purpose of the Study:

• To investigate the effects of amlodipine on exercise capacity and hemodynamic parameters in patients with ischemic cardiomyopathy.
• To evaluate amlodipine's impact on central and regional blood flow in heart failure patients.

Main Methods:

• A single-center, double-blind, randomized placebo-controlled trial involving 32 patients with chronic heart failure.
• Assessment of treadmill exercise capacity, corridor walking times, cardiac output, oxygen uptake, and blood pressure.
• Measurement of calf and renal blood flow at rest and during exercise.

Main Results:

• Amlodipine did not significantly increase exercise capacity compared to placebo (mean difference 70 seconds, p=0.38).
• No significant improvements were observed in walking times, cardiac output, oxygen uptake, heart rate, or mean arterial pressure.
• Treatment with amlodipine did not alter resting or exercise hemodynamics, including calf and renal blood flow.

Conclusions:

• Amlodipine demonstrated a limited role in improving exercise capacity or hemodynamics for patients with ischemic cardiomyopathy.
• The findings suggest amlodipine may not be beneficial for all chronic heart failure patients, particularly those with ischemic disease.
• Further investigation is warranted to clarify amlodipine's potential benefits in non-ischemic heart failure subtypes.